Learnings from 30 years of reported Efficacy and Safety of Vagus Nerve Stimulation (VNS) for Epilepsy Treatment: A critical review

Since its first reported use in humans in 1988 and more than 100,000 subsequent implantations, VNS has generated growing interest in the management of drug-resistant epilepsy (DRE) [1]. These represent around 30% of all epilepsy cases [2]. The average prevalence of epilepsy in the world is estimated at around 7.60 cases/1,000 inhabitants, with an average annual incidence of 67.77 cases/100,000 inhabitants [3]. The functional prognosis and survival associated with this condition are influenced by major trauma and psychiatric and cognitive comorbidities.
Source: Seizure: European Journal of Epilepsy - Category: Neurology Authors: Tags: Review Source Type: research